US$ 29.51
michigan semaglutide gi obstruction lawsuit gastrointestinal class action Subocclusive ileus following off-label high-dose semaglutide use in: Endocrinology, Diabetes & Metabolism Case Reports Volume 2025 Issue 4 (2025) The FDA sent a warning
Description
[Accessed 26/01/2026] 9 at-home treatments for acid reflux
95%CI: 0.70-0.98)

Keeping GLP-1's off-plan avoids the challenge of manufacturer dictated limits on prior authorizations and step therapy - a true danger point for plans wanting the benefits of these drugs with appropriate guard rails to ensure they are used appropriately

Nat Metab 5(2):186192
